Cargando…
Synergistic anti-proliferative activity of JQ1 and GSK2801 in triple-negative breast cancer
BACKGROUND: Triple-negative breast cancer (TNBC) constitutes 10–20% of breast cancers and is challenging to treat due to a lack of effective targeted therapies. Previous studies in TNBC cell lines showed in vitro growth inhibition when JQ1 or GSK2801 were administered alone, and enhanced activity wh...
Autores principales: | Yellapu, Nanda Kumar, Ly, Thuc, Sardiu, Mihaela E., Pei, Dong, Welch, Danny R., Thompson, Jeffery A., Koestler, Devin C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9173973/ https://www.ncbi.nlm.nih.gov/pubmed/35672711 http://dx.doi.org/10.1186/s12885-022-09690-2 |
Ejemplares similares
-
GSK2801 Reverses Paclitaxel Resistance in Anaplastic Thyroid Cancer Cell Lines through MYCN Downregulation
por: Molteni, Elisabetta, et al.
Publicado: (2023) -
optima: an open-source R package for the Tapestri platform for integrative single cell multiomics data analysis
por: Pei, Dong, et al.
Publicado: (2023) -
Discovery and Characterization
of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A
and BAZ2B
por: Chen, Peiling, et al.
Publicado: (2015) -
A High‐Yielding Synthesis of EIDD‐2801 from Uridine
por: Steiner, Alexander, et al.
Publicado: (2020) -
Instant jqGrid
por: Manricks, Gabriel
Publicado: (2013)